Processa Pharmaceuticals, Inc. Proceeds from Loans
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Loans of $142.29 thousand for the 36-month period ending 2014-03-31, per its 10-Q filed 2014-05-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromLoans · last filed 2014-05-14
- Processa Pharmaceuticals, Inc. proceeds from loans for the quarter ending 2014-03-31 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from loans for the quarter ending 2013-12-31 was -$83.51K, a 29923.93% decline year-over-year.
- Processa Pharmaceuticals, Inc. proceeds from loans for the quarter ending 2013-09-30 was $83.51K.
- Processa Pharmaceuticals, Inc. proceeds from loans for the quarter ending 2012-12-31 was $280.00.
- Processa Pharmaceuticals, Inc. proceeds from loans for fiscal 2012 was $142.29K.
| Period end | Proceeds from Loans 3 month | Proceeds from Loans 6 month | Proceeds from Loans 9 month | Proceeds from Loans 12 month | Proceeds from Loans 27 month | Proceeds from Loans 30 month | Proceeds from Loans 33 month | Proceeds from Loans 36 month |
|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $0.00 derived: 10-Q 36 month − 10-K 33 month · filed 2014-05-14 | -$83.51K derived: sum of 2 quarters · filed 2014-05-14 | $0.00 derived: sum of 3 quarters · filed 2014-05-14 | $142.29K 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | -$83.51K derived: 10-K 33 month − 10-Q 30 month · filed 2014-03-27 | $0.00 derived: sum of 2 quarters · filed 2014-03-27 | $142.29K 10-K · filed 2014-03-27 | |||||
| 2013-09-30 | $83.51K derived: 10-Q 30 month − 10-Q/A 27 month · filed 2013-11-08 | $83.51K 10-Q · filed 2013-11-08 | $225.80K 10-Q · filed 2013-11-08 | |||||
| 2013-06-30 | $142.29K 10-Q/A · filed 2013-09-06 | |||||||
| 2012-12-31 | $280.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $142.29K 10-K · filed 2014-03-27 | ||||||
| 2012-09-30 | $142.01K 10-Q · filed 2013-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |